



**Ga-68 PSMA-PET for Prostate Cancer  
Requisition to PET Centre  
TO BE COMPLETED BY THE REFERRING PHYSICIAN**

Patient Name: \_\_\_\_\_

**Histologic Confirmation of Prostate Cancer:**

Gleason Grade Group:  1 (3+3)       2 (3+4)       3 (4+3)       4 (4+4)       5 (5+3/4/5)  
 Not Applicable\*

\*Gleason Grade Group may not be available for patients being assessed for radioligand therapy if the diagnosis of prostate cancer was made from a metastatic deposit, or by an external institution (i.e., out of country)

**PSA measured within 3 months:**

Date: \_\_\_\_/\_\_\_\_/\_\_\_\_ (dd/mm/yyyy)      Value: (ng/mL): \_\_\_\_\_

**Indications (choose one only):**

Initial staging of patients with unfavourable intermediate risk **OR** high-risk prostate cancer when radical radiotherapy is being considered.

**Purpose of PET scan (choose 1):**

**Unfavourable intermediate risk (meets at least two criteria):**

PSA 10-20 ng/mL       Gleason Group 3 (4+3)       Clinical T2b or T2c

**High risk (meets at least one criterion):**

PSA >20 ng/mL **OR**       Gleason Grade Group  $\geq$  4      **OR**       Clinical  $\geq$  T3

- Node positive disease (pN+) or detectable PSA >0.1 ng/mL within 3 months of RP
- BF (rising PSA and >0.1 ng/mL) following RP
- BF (rising PSA and >0.1 ng/mL) post RP + adjuvant or salvage XRT
- BF (rising PSA and >0.1 ng/mL) while on salvage ADT after prior RP (with or without adjuvant or salvage RT)
- BF (rising PSA and >0.1 ng/mL) after treatment for PSMA PET/CT-identified disease
- BF (rising PSA and >2 ng/mL) following primary XRT
- Rising PSA and/or progression on conventional imaging despite prior Androgen Receptor Pathway Inhibitors and chemotherapy for castrate resistant prostate cancer, being considered for publicly funded radioligand therapy.

**Note:** Apply for a PSMA PET scan for case-by-case review through the [PET Access Program](#), for when the PET scan is a problem-solving tool, where the confirmation of the site of disease and/or disease extent may impact clinical management over and above the information provided by conventional imaging.

BF: biochemical failure; RP: radical prostatectomy; XRT: radiotherapy; ADT: androgen deprivation therapy

**Prior therapy for prostate cancer (check all that apply):**

- Focal therapy (Date: \_\_\_\_/\_\_\_\_/\_\_\_\_ dd/mm/yyyy)
- RP (Date: \_\_\_\_/\_\_\_\_/\_\_\_\_ dd/mm/yyyy)
- Primary XRT (Date: \_\_\_\_/\_\_\_\_/\_\_\_\_ dd/mm/yyyy)
- Adjuvant or salvage XRT (Date: \_\_\_\_/\_\_\_\_/\_\_\_\_ dd/mm/yyyy)
- Prior systemic therapies (Date: \_\_\_\_/\_\_\_\_/\_\_\_\_ dd/mm/yyyy) \*
  - Androgen Deprivation     Androgen Receptor Pathway Inhibitor     Chemotherapy

\*Date that continuous salvage systemic therapy (usually ADT) was first commenced

**Physician Signature:** \_\_\_\_\_ **Date:** \_\_\_\_\_